Stockscreener 앱 받기
45.68
1.36%
-0.63
전일 마감가:
$46.31
열려 있는:
$46.51
하루 거래량:
368.15K
Relative Volume:
0.71
시가총액:
$1.26B
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-7.5132
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
+2.26%
1개월 성능:
+1.44%
6개월 성능:
+70.07%
1년 성능:
+203.93%
1일 변동 폭
$45.12
$47.54
1주일 범위
$44.45
$50.50
52주 변동 폭
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
45.68 | 1.28B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS
Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat
Anaptysbio director Marquet sells $530k in shares - Investing.com
Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat
ANAB Stock Price, Forecast & Analysis | ANAPTYSBIO INC (NASDAQ:ANAB) - Chartmill
AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat
ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Australia
What Investors Should Know About a $163K AnaptysBio Insider Sale - sharewise.com
Why AnaptysBio Inc. stock could rally in 2025GDP Growth & Free Safe Capital Growth Stock Tips - Улправда
Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - ET Pharma
Anaptysbio CEO Faga sells $638k in shares By Investing.com - Investing.com South Africa
Anaptysbio CEO Faga sells $638k in shares - Investing.com
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock By Investing.com - Investing.com UK
Anaptysbio CLO Loumeau sells $98,809 in shares By Investing.com - Investing.com Nigeria
Anaptysbio CFO Mulroy sells $112k in shares By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 2,515 Shares - MarketBeat
Eric Loumeau Sells 2,210 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 14,281 Shares - MarketBeat
Anaptysbio CLO Loumeau sells $98,809 in shares - Investing.com
The Technical Signals Behind (ANAB) That Institutions Follow - Stock Traders Daily
What AnaptysBio (ANAB)'s Royalty Spin-Off Plan Means For Shareholders - Sahm
AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Shares Gap Down Following Insider Selling - MarketBeat
Is AnaptysBio Inc. stock positioned for digital transformationGrip and Outsole Review & HOKA model picks for your routine - Улправда
AnaptysBio (NASDAQ:ANAB) Upgraded at UBS Group - MarketBeat
AnaptysBio Moves to Toss GSK/Tesaro Repudiation Claim Over Jemperli Royalties - prismedia.ai
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock - Investing.com
Anaptysbio CFO Mulroy sells $86k in shares By Investing.com - Investing.com Canada
Anaptysbio CFO Mulroy sells $86k in shares - Investing.com India
What dividend safety score for AnaptysBio Inc. stockPortfolio Return Report & AI Optimized Trading Strategy Guides - ulpravda.ru
AnaptysBio CMO Lizzul sells $100k in stock By Investing.com - Investing.com South Africa
Anaptysbio chief legal officer Loumeau sells $439k in stock By Investing.com - Investing.com Canada
Anaptysbio chief legal officer Loumeau sells $439k in stock - Investing.com
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anaptysbio Inc 주식 (ANAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Marquet Magda | Director |
Jan 15 '26 |
Sale |
48.23 |
11,000 |
530,531 |
9,930 |
4.73%
0.92%
자본화:
|
볼륨(24시간):